Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker UTHR · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hyper… NCT07923591 · Pulmonary Hypertension Associated With Chronic Obstructive… treprostinil SMI (treprostinil inhalation spray), Placebo (… | UTHR United Therapeutics | Phase 2 | Not yet recruiting | 40 | May 2028 | Registry ↗ |
| Nov 6, 2026 | An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary H… NCT07923526 · Pulmonary Hypertension Associated With Chronic Obstructive… treprostinil SMI (treprostinil inhalation spray) | UTHR United Therapeutics | Phase 2/3 | Not yet recruiting | 400 | Sep 2034 | Registry ↗ |
| Oct 19, 2026 | Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease NCT04905693 · Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer | UTHR United Therapeutics | Phase 3 | Enrolling by invitation | 1,850 | Dec 2029 | Registry ↗ |
| Oct 15, 2026 | Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulm… NCT05255991 · Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease Placebo, Inhaled Treprostinil | UTHR United Therapeutics | Phase 3 | Completed | 597 | Jun 30, 2025 | Registry ↗ |
| Oct 6, 2026 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-… NCT03683186 · PAH, Pulmonary Hypertension Ralinepag | UTHR United Therapeutics | Phase 3 | Enrolling by invitation | 1,000 | Dec 2026 | Registry ↗ |
| Sep 9, 2026 | Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD NCT07224763 · ESRD (End-Stage Renal Disease), Kidney Transplantation GGTA1 KO Thymokidney | UTHR United Therapeutics | Phase 1/2 | Recruiting | 50 | Nov 2029 | Registry ↗ |
| Aug 26, 2026 | DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Inter… NCT06388421 · Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pu… Prospective study assessments | UTHR United Therapeutics | — | Recruiting | 900 | Sep 1, 2030 | Registry ↗ |
| Jul 13, 2026 | Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fib… NCT05943535 · Progressive Pulmonary Fibrosis, Interstitial Lung Disease Placebo, Inhaled Treprostinil | UTHR United Therapeutics | Phase 3 | Recruiting | 698 | Nov 2027 | Registry ↗ |
| Jul 6, 2026 | Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 P… NCT04084678 · Pulmonary Hypertension, Pulmonary Arterial Hypertension Ralinepag, Placebo | UTHR United Therapeutics | Phase 3 | Terminated | 10 | Apr 12, 2023 | Registry ↗ |
| Jun 16, 2026 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patien… NCT03626688 · PAH, Pulmonary Hypertension Ralinepag, Placebo | UTHR United Therapeutics | Phase 3 | Completed | 687 | Dec 31, 2025 | Registry ↗ |
| May 28, 2026 | Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection NCT05776225 · Interstitial Lung Disease, Pulmonary Hypertension Right heart catheterization (RHC) | UTHR United Therapeutics | — | Completed | 314 | Mar 13, 2026 | Registry ↗ |
| May 27, 2026 | Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmona… NCT03794583 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disea… Inhaled treprostinil solution | UTHR United Therapeutics | Phase 3 | Terminated | 41 | Nov 29, 2022 | Registry ↗ |
| May 5, 2026 | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis NCT04708782 · Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease Placebo, Inhaled Treprostinil | UTHR United Therapeutics | Phase 3 | Completed | 598 | Feb 2, 2026 | Registry ↗ |
| Apr 2, 2026 | ADAPT - A Patient Registry of the Real-world Use of Orenitram® NCT03045029 · Pulmonary Arterial Hypertension Oral treprostinil | UTHR United Therapeutics | — | Active, not recruiting | 300 | Mar 2027 | Registry ↗ |
| Mar 27, 2026 | Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD NCT06878560 · ESRD (End-Stage Renal Disease), Kidney Transplantation 10 GE Xenokidney | UTHR United Therapeutics | Phase 1/2 | Recruiting | 50 | Oct 2028 | Registry ↗ |
| Dec 9, 2025 | A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil The… NCT05203510 · Pulmonary Arterial Hypertension Parenteral Treprostinil, Oral Treprostinil | UTHR United Therapeutics | Phase 4 | Active, not recruiting | 52 | Apr 30, 2026 | Registry ↗ |
| Mar 30, 2025 | Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to… NCT02276872 · PAH oral treprostinil | UTHR United Therapeutics | Phase 2 | Completed | 32 | Jul 20, 2017 | Registry ↗ |
| Jan 16, 2025 | Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin NCT05060315 · Pulmonary Arterial Hypertension Remunity Pump for Remodulin | UTHR United Therapeutics | — | Terminated | 9 | Dec 31, 2024 | Registry ↗ |
| Nov 1, 2024 | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Cur… NCT03950739 · Pulmonary Arterial Hypertension Treprostinil Inhalation Powder | UTHR United Therapeutics | Phase 1 | Completed | 51 | Aug 22, 2023 | Registry ↗ |
| Jun 18, 2024 | Open-Label Study of Oral Treprostinil in Digital Ulcers NCT00848107 · Systemic Sclerosis treprostinil diethanolamine | UTHR United Therapeutics | Phase 2 | Terminated | 115 | Sep 2011 | Registry ↗ |
| Mar 5, 2024 | Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn NCT02261883 · Persistent Pulmonary Hypertension of the Newborn IV Remodulin, Placebo | UTHR United Therapeutics | Phase 2 | Terminated | 42 | Sep 27, 2022 | Registry ↗ |
| Jan 5, 2024 | TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial… NCT03055221 · Pulmonary Arterial Hypertension Intravenous Treprostinil | UTHR United Therapeutics | Phase 4 | Completed | 20 | Feb 25, 2014 | Registry ↗ |
| Jan 3, 2024 | A Pharmacokinetic Substudy of the TDE-PH-304 Protocol NCT01934582 · Pulmonary Arterial Hypertension UT-15C SR, treprostinil diethanolamine | UTHR United Therapeutics | Phase 3 | Completed | 13 | Nov 2013 | Registry ↗ |
| Jan 3, 2024 | Rapid Switch From Flolan to Remodulin in the Outpatient Clinic NCT00643604 · Hypertension, Pulmonary treprostinil sodium | UTHR United Therapeutics | Phase 4 | Terminated | 7 | Jan 2010 | Registry ↗ |
| Jan 3, 2024 | Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Fiv… NCT00439946 · Pulmonary Arterial Hypertension treprostinil, Crono Five ambulatory pump | UTHR United Therapeutics | Phase 4 | Terminated | 8 | Sep 2009 | Registry ↗ |
| Jan 3, 2024 | FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension… NCT00325403 · Pulmonary Hypertension Oral treprostinil (UT-15C) Sustained Release Tablets, Place… | UTHR United Therapeutics | Phase 3 | Completed | 349 | Apr 2011 | Registry ↗ |
| Jan 2, 2024 | Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial… NCT00147199 · Pulmonary Hypertension Inhaled treprostinil, Placebo inhalation solution | UTHR United Therapeutics | Phase 3 | Completed | 235 | Oct 2007 | Registry ↗ |
| Dec 28, 2023 | Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine NCT00775463 · Systemic Sclerosis, Scleroderma treprostinil diethanolamine, placebo | UTHR United Therapeutics | Phase 2 | Completed | 148 | Mar 2011 | Registry ↗ |
| Dec 27, 2023 | Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® NCT01477333 · Pulmonary Arterial Hypertension UT-15C SR, Tyvaso Inhalation Solution | UTHR United Therapeutics | Phase 2 | Completed | 18 | Nov 2013 | Registry ↗ |
| Dec 19, 2023 | Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients NCT01884038 · Liver Transplant treprostinil sodium, Placebo | UTHR United Therapeutics | Phase 2/3 | Withdrawn | 0 | Jun 2010 | Registry ↗ |
| Nov 24, 2023 | A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participant… NCT03496623 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disea… Inhaled treprostinil solution, Placebo solution | UTHR United Therapeutics | Phase 3 | Terminated | 188 | Oct 13, 2022 | Registry ↗ |
| Aug 7, 2023 | EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arte… NCT03497689 · Pulmonary Arterial Hypertension Intravenous/Subcutaneous Treprostinil; Oral Treprostinil | UTHR United Therapeutics | Phase 4 | Completed | 36 | May 11, 2022 | Registry ↗ |
| Dec 2, 2022 | An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE NCT02633293 · Pulmonary Hypertension, Interstitial Lung Disease Inhaled Treprostinil | UTHR United Therapeutics | Phase 2/3 | Terminated | 243 | Aug 1, 2021 | Registry ↗ |
| Jul 27, 2022 | Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE NCT02630316 · Pulmonary Hypertension, Interstitial Lung Disease Inhaled Treprostinil, Placebo | UTHR United Therapeutics | Phase 2/3 | Completed | 326 | Dec 26, 2019 | Registry ↗ |
| Jun 2, 2022 | An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension NCT01560637 · Pulmonary Arterial Hypertension UT-15C (treprostinil diolamine) | UTHR United Therapeutics | Phase 3 | Completed | 471 | Aug 12, 2021 | Registry ↗ |
| Dec 22, 2021 | Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension NCT02279745 · Pulmonary Arterial Hypertension Ralinepag | UTHR United Therapeutics | Phase 2 | Completed | 45 | Mar 29, 2021 | Registry ↗ |
| Oct 12, 2021 | A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High… NCT03857841 · Bronchopulmonary Dysplasia UNEX-42, Phosphate-buffered saline | UTHR United Therapeutics | Phase 1 | Terminated | 3 | May 20, 2021 | Registry ↗ |
| May 10, 2021 | An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial… NCT01027949 · Pulmonary Arterial Hypertension Oral Treprostinil | UTHR United Therapeutics | Phase 3 | Completed | 894 | Feb 12, 2020 | Registry ↗ |
| Mar 16, 2021 | Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH NCT03888365 · Pulmonary Arterial Hypertension Treprostinil, Non-Treprostinil PAH Medications | UTHR United Therapeutics | — | Completed | 43 | Sep 19, 2019 | Registry ↗ |
| Dec 9, 2020 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Ce… NCT03098030 · Small Cell Lung Cancer Dinutuximab, Irinotecan | UTHR United Therapeutics | Phase 2/3 | Completed | 483 | Jan 27, 2020 | Registry ↗ |
| Nov 10, 2020 | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preser… NCT03037580 · Pulmonary Hypertension, Heart Failure With Preserved Ejecti… Oral treprostinil, Placebo | UTHR United Therapeutics | Phase 3 | Terminated | 84 | Dec 3, 2019 | Registry ↗ |
| Oct 22, 2020 | Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF NCT03043651 · Pulmonary Hypertension Associated With HFpEF Oral treprostinil | UTHR United Therapeutics | Phase 3 | Terminated | 48 | Mar 2, 2020 | Registry ↗ |
| Jul 14, 2020 | Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension NCT02279160 · Pulmonary Arterial Hypertension APD811, Placebo | UTHR United Therapeutics | Phase 2 | Completed | 61 | Jun 2017 | Registry ↗ |
| Feb 13, 2020 | Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monothe… NCT01560624 · Pulmonary Arterial Hypertension Treprostinil Diolamine, Placebo | UTHR United Therapeutics | Phase 3 | Completed | 690 | Jun 24, 2018 | Registry ↗ |
| Aug 5, 2019 | Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Pati… NCT02693171 · Neuroblastoma Dinutuximab | UTHR United Therapeutics | — | Terminated | 13 | Dec 19, 2016 | Registry ↗ |
| Nov 1, 2017 | Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (… NCT02999906 · Pulmonary Arterial Hypertension Oral Treprostinil, Placebo | UTHR United Therapeutics | Phase 3 | Withdrawn | 0 | Dec 2021 | Registry ↗ |
| Oct 17, 2017 | Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects… NCT02847260 · Pulmonary Arterial Hypertension Remodulin | UTHR United Therapeutics | Phase 4 | Completed | 39 | Mar 2014 | Registry ↗ |
| Aug 2, 2017 | FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a P… NCT00325442 · Pulmonary Hypertension Oral treprostinil (UT-15C) sustained release tablets, Place… | UTHR United Therapeutics | Phase 3 | Completed | 354 | Sep 2008 | Registry ↗ |
| May 9, 2017 | Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin… NCT02893995 · Pulmonary Arterial Hypertension Slow Dose Titration Group of Subcutaneous Treprostinil, Rap… | UTHR United Therapeutics | Phase 4 | Withdrawn | 0 | Apr 2018 | Registry ↗ |
| May 9, 2017 | An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin®… NCT02882126 · Pulmonary Arterial Hypertension Subcutaneous Treprostinil | UTHR United Therapeutics | Phase 4 | Withdrawn | 0 | Jun 2021 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:48 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances